Poster Presentations Session III
Poster Presentations Session III Tuesday, May 19, 2015
POSTERS SET-UP: 8:15 AM - 8:30 AM
POSTERS DISPLAY HOURS: 8:30 AM - 2:15 PM
POSTER AUTHOR DISCUSSION: 1:15 PM - 2:15 PM
POSTERS DISMANTLE: 2:15 PM


Poster display locations are shown below the poster codes
CARDIOVASCULAR DISORDERS - Clinical Outcomes Studies
PCV1
A1
IMPACT OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON THE RISK OF CARDIOVACULAR-RELATED HSOPITALIZATIONS
Kathe NJ1, Shah AB2, Said Q1
1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2University of Arkansas for Medical Sciences, LITTLE ROCK, AR, USA

PCV2
A2
WITHDRAWN

PCV3
A3
A DESCRIPTIVE ANALYSIS OF PATIENT CHARACTERISTICS, BLEEDING AND RECURRENCE RISK AMONG U.S VETERAN PATIENTS DIAGNOSED WITH VENOUS THROMBOEMBOLISM
Xie L1, Du J1, Kariburyo MF1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Columbia University, New York, NY, USA

PCV4
A4
NOVEL PHARMACIST-GUIDED PHARMACOGENETIC SERVICE LOWERS WARFARIN-RELATED HOSPITALIZATIONS
Kim K1, Gor D1, Walton SM1, Galanter WL1, Duarte J1, Krishnan JA1, Bauman JL1, Cavallari LH2, Nutescu EA1
1University of Illinois at Chicago, Chicago, IL, USA, 2University of Florida, Gainesville, FL, USA

PCV5
A5
CLINICAL OUTCOMES AND TREATMENT PATTERNS OF VENOUS THROMBOEMBOLISM AMONG CANCER PATIENTS IN A LARGE COMMERCIAL DATABASE
Masseria C1, Kariburyo MF2, Mardekian J1, Lee T1, Phatak H3, Baser O4, Xie L2
1Pfizer Inc., New York, NY, USA, 2STATinMED Research, Ann Arbor, MI, USA, 3Bristol-Myers Squibb Company, Princeton, NJ, USA, 4STATinMED Research, Columbia University, New York, NY, USA

PCV6
A6
CONCOMITANT SLEEP DISORDER SIGNIFICANTLY ENHANCES THE RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH PSORIASIS
Chiu H1, Chiang Y2, Hsieh C2, Tsai Y3, Huang W3, Tsai T1
1National Taiwan University Hospital, Taipei, Taiwan, 2National Yang-Ming University, Taipei, Taiwan, 3National Yang Ming University, Taipei, Taiwan

PCV7
A7
VALIDATION OF HYPERTENSIVE PATIENT IDENTIFICATION AND EFFECT OF VARYING OBSERVATION TIME FROM ADMINISTRATIVE CLAIMS DATA USING ELECTRONIC MEDICAL RECORDS
Liu J1, Ma Q1, Willey V2, Rodenberger D1, Barron J1
1HealthCore, Inc, Wilmington, DE, USA, 2HealthCore Inc., Wilmington, DE, USA

PCV8
A8
COMPARATIVE EFFECTIVENESS OF RIVAROXABAN AND STANDARD ANTICOAGULANT THERAPIES FOR PREVENTION OF PRIMARY VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY
Shewale AR, Martin BC
University of Arkansas for Medical Sciences, Little Rock, AR, USA

PCV9
A9
ESTIMATING THE LIFETIME CLINICAL RISK/BENEFITS OF APIXABAN VERSUS EDOXABAN IN NON-VALVULAR ATRIAL FIBRILLATION
Phatak H1, Dorian P2, Kongnakorn T3, Lanitis T4, Liu X5, Mardekian J6, Lawrence J7, Lip G8
1Bristol-Myers Squibb Company, Princeton, NJ, USA, 2University of Torono, Toronto, ON, Canada, 3Evidera, Bangkok, Thailand, 4Evidera, London, UK, 5Pfizer, New York, NY, USA, 6Pfizer Inc., New York, NY, USA, 7BMS, Princeton, NJ, USA, 8University of Birmingham, Birmingham, UK

PCV10
A10
CARDIOVASCULAR SAFETY WITH THE CONCURRENT USE OF MOOD STABILIZERS OR ATYPICAL ANTIPSYCHOTICS AND STIMULANTS IN CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER AND BIPOLAR DISORDER
Rane P, Bali V, Aparasu RR
University of Houston, Houston, TX, USA

PCV11
A11
DISCONTINUATION OF STATIN USE AFTER HEMODIALYSIS AND THE RISK OF CARDIOVASCULAR DISEASES
Liu Y1, Huang W1, Chang W1, Wen Y2, Tsai Y1
1National Yang Ming University, Taipei, Taiwan, 2Chang Gung University, Taoyuan, Taiwan

PCV12
A12
THE IMPACT OF RACE ON THE ASSOCIATION BETWEEN A NOVEL GENOTYPE-GUIDED PERSONALIZED WARFARIN SERVICE AND CLINICAL OUTCOMES IN AN ETHNICALLY DIVERSE POPULATION
Manzoor B1, Duarte J1, Lee J1, Galanter WL1, Walton SM1, Galanter N1, Krishnan JA1, Bauman JL1, Cavallari LH2, Nutescu EA1
1University of Illinois at Chicago, Chicago, IL, USA, 2University of Florida, Gainesville, FL, USA

PCV13
WITHDRAWN

PCV14
A13
EHEALTH IN THE MANAGEMENT OF CHRONIC DISEASES: A REVIEW OF PROGRAM EFFICACY
Kiss N1, Fortier K2
1Department of Health Economics, Centre for Public Health, Medical University of Vienna, Vienna, Austria, 2Compass Strategic Consulting, Inc., New Haven, CT, USA

PCV15
A14
COMPARISON OF APIXABAN, DABIGATRAN, RIVAROXABAN, AND EDOXABAN IN THE ACUTE TREATMENT AND PREVENTION OF VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Cohen AT1, Batson S2, Hamilton M3, Masseria C4, Mitchell S2, Phatak H3
1King's College, London, UK, 2Abacus International, Bicester, UK, 3BMS, Princeton, NJ, USA, 4Pfizer Inc., New York, NY, USA

PCV16
A15
EFFICACY AND SAFETY OF AMLODIPINE AND BISOPROLOL IN HYPERTENSION TREATMENT: A SYSTEMATIC REVIEW
Fujii RK1, Restrepo M2, Pepe C3, Fernandes RA3, Haas L4, Junqueira M1
1Merck Serono, São Paulo, Brazil, 2Merck Serono, Bogota, Colombia, 3Grupo Resulta, São Paulo, Brazil, 4Sense Company, Rio de Janeiro, Brazil

PCV17
A16
EFFECTIVENESS AND COST-EFFECTIVENESS OF CATHETER-DIRECTED THROMBOLYSIS IN MASSIVE PULMONARY EMBOLISM
Kostyuk A1, Akanov A2, Garkalov K1
1Kazakh Medical University for Continuing Education, Astana, Kazakhstan, 2Astana Medical University, Astana, Kazakhstan

PCV18
A17
MIPOMERSEN FOR TREATMENT OF HYPERCHOLESTEREMIA: EVIDENCE REVIEW AND META ANALYTIC EVALUATION OF RANDOMIZED CONTROLLED TRIALS
Bardia A1, Garg G2
1Invaluesys Research, Hyderabad, India, 2Invaluesys Research, Burgdorf, Germany

PCV19
A18
THE USE OF LOW MOLECULAR WEIGHT HEPARIN AND PNEUMATIC COMPRESSION DEVISES FOR DEEP VEIN THROMBOSIS PROPHYLAXIS IN MAJOR TRAUMA PATIENTS: A COMPARATIVE EFFECTIVENESS ANALYSIS
Alahmari AK, Almalki ZS, Guo JJ
University of Cincinnati, Cincinnati, OH, USA

PCV20
A19
THE ASSOCIATION BETWEEN CHOICE OF BALANCED INTRAVENOUS CRYSTALLOID AND SUBSEQUENT MAJOR IN-HOSPITAL OUTCOMES AMONG ADULT PATIENTS UNDERGOING CARDIAC SURGERY
Raghunathan K1, Khangulov VS2, Peyerl FW2, Shaw AD3
1Durham VA Medical Center, Durham, NC, USA, 2Boston Strategic Partners, Inc., Boston, MA, USA, 3Vanderbilt University Medical Center, Nashville, TN, USA

PCV21
A20
MODELLING THE CLINICAL AND ECONOMIC OUTCOMES OF VARIATIONS IN INTENSITY OF VALSARTAN-CENTRIC REGIMENS FOR HYPERTENSION
Alshayban DM
University of Arizona, Tucson, AZ, USA

PCV22
A21
COMPARE EARLY MORTALITY AFTER AORTIC VALVE REPLACEMENT WITH MECHANICAL PROSTHETIC VS BIOPROSTHETIC VALVES AMONG MEDICARE BENEFICIARIES
Du D1, McKean S2, Kelman JA3, Laschinger J1, Johnson C2, Warnock R2, Worrall CM4, Sedrakyan A5, Encinosa W6, MaCurdy TE2, Izurieta HS1
1Food and Drug Administration, Silver Spring, MD, USA, 2Acumen LLC, Burlingame, CA, USA, 3CMS, Washington DC, DC, USA, 4CMS, Baltimore, MD, USA, 5Weill Cornell Medical College, New York City, NY, USA, 6Agency for Healthcare Research and Quality, Rockville, MD, USA

PCV23
B1
COMPARATIVE EFFECTIVENESS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN HEART FAILURE
Sharma M, Johnson ML, Chen H, Aparasu R
University of Houston, Houston, TX, USA

PCV24
B2
MULTIFACETED INTERVENTIONS IMPROVE MEDICATION ADHERENCE IN MEDICAID PATIENTS PRESCRIBED HYPOGLYCEMICS, STATINS, AND/OR ANTIHYPERTENSIVES
Gao W1, Keleti D1, Donia T1, Downey TW1, Megargell L2, Kreitman J3, Michael KE1, Gelzer AD1
1The AmeriHealth Caritas Family of Companies, Philadelphia, PA, USA, 2PerformRx, Philadelphia, PA, USA, 3AmeriHealth Caritas Pennsylvania, Harrisburg, PA, USA

PCV25
B3
EVALUATION OF BLEEDING OUTCOMES LINKED TO NEW ORAL ANTICOAGULANTS: REVIEW OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)
Jacobs DM, Hempel C, Feuerstein S
University at Buffalo, Buffalo, NY, USA

PCV26
B4
ANTIHYPERTENSIVE DRUG UTILIZATION IN ELDERLY OUTPATIENTS IN SERBIA
Tomas A, Horvat O, Paut Kusturica M, Tomic Z, Ban M, Sabo A
Faculty of Medicine, Novi Sad, Serbia and Montenegro

PCV27
B5
USE OF SELECTIVE-SEROTONIN REUPTAKE INHIBITORS AND PLATELET AGGREGATION INHIBITORS AMONG INDIVIDUALS WITH CO-OCCURRING HEART DISEASE AND DEPRESSION OR ANXIETY
Thornton JD, Agarwal P, Sambamoorthi U
West Virginia University, Morgantown, WV, USA

PCV28
B6
VOLUME AND STRUCTURE OF ANTIHYPERTENSIVE DRUGS CONSUMPTION IN UKRAINE
Iakovlieva L, Mishchenko O, Bezditko N, Gerasymova O, Kyrychenko O, Tkachova O, Matyashova N
National University of Pharmacy, Kharkiv, Ukraine

PCV29
B7
OUTCOMES, HEALTH COSTS AND USE OF STATINS IN 6,226 PATIENTS ADMITTED IN 2011 FOR AN ACUTE CORONARY SYNDROME (ACS) OCCURRING IN A LARGE COMMUNITY SETTING OF 2,989,512 SUBJECTS
Maggioni AP1, Cinconze E2, Rossi E2, De Rosa M2, Esposito I3, Martini N3
1ANMCO Research Center, Florence, Italy, 2CINECA Interuniversity Consortium, Casalecchio di Reno, Italy, 3Accademia Nazionale di Medicina, Roma, Italy

PCV30
B8
PHYSICIAN'S ADHERENCE TO TREATMENT GUIDELINES IN DEEP VEIN THROMBOSIS AT AN INDIAN TERTIARY HEALTHCARE FACILITY
Tiwari P1, Sunarikani R1, Malhotra S2
1NIPER MOHALI INDIA, MOHALI, India, 2Private Hospital, MOHALI, India

PCV31
B9
TRENDS IN ANTIHYPERTENSIVE MEDICATION USE IN US OFFICE-BASED PRACTICES: ARE ELDERLY PATIENTS TREATED DIFFRERENTLY?
Gu A1, Yue Y2, Argulian E3
1St. John's University, Jamaica, NY, USA, 2Baruch College/CUNY, New York, NY, USA, 3Mount Sinai St. Luke's Hospital, New York, NY, USA

PCV32
B10
COMPARISON OF DIFFERENT METABOLIC SYNDROME CRITERIA AND INDIVIDUAL RISK FACTORS IN THE RISK PREDICTION OF CARDIOVASCULAR AND CHRONIC DISEASES
Bhounsule P, Peterson AM
University of the Sciences in Philadelphia, Philadelphia, PA, USA

PCV33
B11
HYPERKALEMIA IS HIGHLY PREVALENT IN PATIENTS WITH CARDIORENAL COMORBIDITIES COMPARED TO PATIENTS WITHOUT THESE COMORBIDITIES
Latts LM1, Reaven NL2, Funk SE2, McGaughey KJ3, Adamson RT4
1LML Health Solutions LLC, Denver, CO, USA, 2Strategic Health Resources, La Canada, CA, USA, 3California Polytechnic State University, San Luis Obispo, CA, USA, 4Barnabas Health, West Orange, NJ, USA

PCV34
B12
VENOUS THROMBOEMBOLISM PREVALENCE IN FRENCH AND US HOSPITALS: COMPARISON ON THE BASIS OF THE NATIONAL DATA BASES
Allaert F1, Quantin C2, Benzenine M2
1Medical evaluation Chair ESC Dijon, Dijon, France, 2university hospital Dijon, Dijon, France

PCV35
B13
THE PREVALENCE AND ODDS-RATIOS OF SELF-REPORTED DIAGNOSIS OF HYPERTENSION AMONG US ADULTS BY RACIAL/ETHNIC SUBGROUPS, EXAMINING THE JOINT EFFECT OF MULTIPLE RISK FACTORS: NATIONAL HEALTH INTERVIEW SURVEY, 2004 - 2013
Godwin O, Brown LM
Chapman University, Irvine, CA, USA

PCV36
B14
GEOGRAPHIC DIFFERENCES IN AVAILABILITY OF ANTIHYPERTENSIVE MEDICATIONS: A COMPARISON OF AUSTRALIA, CANADA, SAUDI ARABIA, UK, AND THE US
Almutairi H1, Alzarea AI1, Seoane-Vazquez E1, Mekary R2
1MCPHS University, Boston, MA, USA, 2MCPHS University, N/A, MA, USA

PCV37
B15
A RETROSPECTIVE DATABASE STUDY TO INVESTIGATE THE MORBIDITY AND PHARMACEUTICAL INTERVENTION OF PULMONARY ARTERIAL HYPERTENSION IN JAPAN
Sawachi S
Pfizer Japan Inc., Tokyo, Japan

PCV38
B16
INCREASED RISK OF ARRHYTHMIA IN PATIENTS WITH PSORIASIS: A MATCHED COHORT STUDY
Chang W1, Chiu H2, Huang W1, Wen Y3, Tsai Y1, Tsai T2
1National Yang Ming University, Taipei, Taiwan, 2National Taiwan University Hospital, Taipei, Taiwan, 3Chang Gung University, Taoyuan, Taiwan

PCV39
B17
LIFE'S SIMPLE 7 AND CARDIOVASCULAR DISEASE RISK KNOWLEDGE IN HONG KONG
Lee V, Kong KY, Fong F, Ngai L, Wong V, Yan BP
Chinese University of Hong Kong, Shatin, Hong Kong

PCV40
B18
FACTORS THAT NEGATIVELY INFLUENCE THE PREDICTION OF WARFARIN STABLE DOSE WHEN EMPLOYING A GENOTYPE-GUIDED APPROACH
Lee W1, Chumnumwat S1, Duarte J1, Gratie D1, Galanter WL1, Walton SM1, Krishnan JA1, Bauman JL1, Cavallari LH2, Nutescu EA1
1University of Illinois at Chicago, Chicago, IL, USA, 2University of Florida, Gainesville, FL, USA

PCV41
B19
EXAMINING ASSOCIATION BETWEEN LIVER ENZYMES AND LIPID LEVELS AMONGST ADULTS IN THE UNITED STATES: A CROSS SECTIONAL STUDY
Sakharkar P, Deb S
Roosevelt University College of Pharmacy, Schaumburg, IL, USA

PCV42
B20
STATIN USE AND RISK OF DEVELOPING DIABETES: A NETWORK META-ANALYSIS
Thakker D1, Nair SR1, Jamdade V2, Shaikh S1, Pagada A2, Oomman S1, Malik A1
1Capita Ind Pvt. Ltd., Mumbai, India, 2Capita India Pvt. Ltd., Mumbai, India

PCV43
B21
COSTS AND OUTCOMES OF PATIENTS ADMITTED FOR A CARDIOVASCULAR ISCHEMIC DISEASE IN A LARGE COMMUNITY SETTING OF 2,989,512 SUBJECTS OF THE ITALIAN NATIONAL HEALTH SERVICE (NHS)
Maggioni AP1, Cinconze E2, Rossi E2, De Rosa M2, Esposito I3, Martini N3
1ANMCO Research Center, Florence, Italy, 2CINECA Interuniversity Consortium, Casalecchio di Reno, Italy, 3Accademia Nazionale di Medicina, Roma, Italy

PCV44
C1
ASSESSMENT OF DRUG UTILIZATION PATTERN AND CLINICAL OUTCOME IN PREGNANCY INDUCED HYPERTENSION IN TERITARY CARE HOSPITAL
Bandari mM
kakatiya university, warangal, India

CARDIOVASCULAR DISORDERS - Cost Studies
PCV45
C2
ESTIMATING THE BUDGET IMPACT OF CLEVIDIPINE FOR THE MANAGEMENT OF PERIOPERATIVE BLOOD PRESSURE IN CARDIAC SURGERY: A US PERSPECTIVE
Baker TM1, Kuan R2, Crothers TA3, Wang Y3
1ICON Plc, Morristown, NJ, USA, 2Independent, Portland, OR, USA, 3The Medicines Company, Parsippany, NJ, USA

PCV46
C3
ECONOMIC IMPLICATIONS OF INCREASED UTILIZATION OF 5% ALBUMIN FOR FLUID RESUSCITATION POST ON-PUMP CARDIAC PROCEDURES IN US HOSPITALS
Runken MC1, Khangulov VS2, Munson SH2, Peyerl FW2, Bunke M1
1Grifols, Inc., Research Triangle Park, NC, USA, 2Boston Strategic Partners, Inc., Boston, MA, USA

PCV47
C4
EXPECTED COST OF DRUG THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION, DIABETES MELLITUS AND DYSLIPIDEMIA IN CHILE: A PROBABILISTIC ANALYSIS
Balmaceda C1, Espinoza MA2
1Instituto de Salud Pública, Santiago, Chile, 2Pontificia Universidad Catolica de Chile, Santiago, Chile

PCV48
C5
COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT OF CONCOR® AM VERSUS BISOPROLOL PLUS AMLODIPINE IN SYSTEMIC ARTERIAL HYPERTENSION TREATMENT, FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM
Fujii RK1, Restrepo M2, Fernandes RA3, Haas L4, Pepe C3, Junqueira M1
1Merck Serono, São Paulo, Brazil, 2Merck Serono, Bogota, Colombia, 3Grupo Resulta, São Paulo, Brazil, 4Sense Company, Rio de Janeiro, Brazil

PCV49
C6
ESTIMATED SAVINGS IN MEDICAL COSTS WHEN NEW ORAL ANTICOAGULANTS ARE USED FOR THE TREATMENT OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION AND VENOUS THROMBOEMBOLISM VS. WARFARIN IN THE U.S
Amin A1, Bruno A2, Trocio J3, Lin J4, Lingohr-Smith M4
1University of California, Irvine, CA, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Pfizer, New York, NY, USA, 4Novosys Health, Green Brook, NJ, USA

PCV50
C7
A RETROSPECTIVE ANALYSIS OF HEALTH CARE RESOURCE UTILIZATION AND THE ECONOMIC BURDEN AMONG U.S. LONG-TERM CARE FACILITY PATIENTS DIAGNOSED WITH STROKE
Huang A1, Shrestha S1, Baser O2, Yuce H3, Wang L1
1STATinMED Research, Plano, TX, USA, 2STATinMED Research, Columbia University, New York, NY, USA, 3City University of New York & STATinMED Research, New York, NY, USA

PCV51
C8
MEDICATION COST IMPLICATION FOR THE MANAGEMENT OF HYPERTENSION AND DIABETES IN NIGER DELTA: TERTIARY HOSPITAL BASED STUDY IN BAYELSA STATE, NIGERIA
Ganiyu KA1, Erah PO2
1Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria, 2University of Benin, Benin City, Nigeria

PCV52
C9
ESTIMATING THE COST OF ILLNESS OF GIANT CELL ARTERITIS
Babigumira JB1, Li M1, Boudreau DM1, Best JH2, Garrison LP1
1University of Washington, Seattle, WA, USA, 2Genentech, Inc, South San Francisco, CA, USA

PCV53
C10
ACUTE, SHORT-TERM AND LONG-TERM COSTS OF CARDIOVASCULAR EVENTS AMONG HYPERLIPIDEMIA PATIENTS
Paoli CJ1, Gandra SR1, Henk HJ2
1Amgen, Inc., Thousand Oaks, CA, USA, 2Optum, Eden Prarie, MN, USA

PCV54
C11
TREATMENT EFFECTS ON THE COST BURDEN OF HOSPITALIZATIONS IN PATIENTS WITH CHRONIC SYSTOLIC HEART FAILURE
Kansal A1, Kielhorn A2, Dorman E1, Krotneva S3, Zheng Y1, Patel H2, Borer J4
1Evidera, Bethesda, MD, USA, 2Amgen, Thousand Oaks, CA, USA, 3Evidera, St-Laurent, QC, Canada, 4State University of New York Downstate Medical Center, Brooklyn and New York, NY, USA

PCV55
C12
DIRECT MEDICAL BURDEN AND READMISSION RATES AMONG NON-ELDERLY PATIENTS WITH ACUTE ISCHEMIC STROKE IN THE UNITED STATES
Johnson BH1, Bonafede MM1, Watson C2
1Truven Health Analytics, Cambridge, MA, USA, 2Biogen Idec, Cambridge, MA, USA

PCV56
C13
INCREMENTAL COSTS OF GIANT CELL ARTERITIS IN FRANCE
Costa N1, Pugnet G2, Bouscaren N1, Bourrel R3, Lapyere-Mestre M4, Sailler L2, Molinier L1
1Univeristy Hospital of Toulouse, Toulouse, France, 2University of Toulouse III, Toulouse, France, 3Regional Health Insurance, Toulouse, France, 4INSERM UMR 1027, Toulouse, France

PCV57
C14
SYSTEMATIC REVIEW OF THE SOCIETAL COST AND ECONOMIC BURDEN ASSOCIATED WITH CHRONIC HEART FAILURE
Allen F1, Haroun R2, King D3
1Novartis Pharmaceuticals UK Limited, Surrey, UK, 2Novartis Pharma AG, Basel, Switzerland, 3Abacus International, Bicester, UK

PCV58
C15
LONG-TERM ECONOMIC BURDEN ASSOCIATED WITH CARDIOVASCULAR EVENTS AMONG HIGH-RISK PATIENTS WITH HYPERLIPIDEMIA
Fox KM1, Wang L2, Gandra SR3, Quek RG3, Li L2, Baser O4
1Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 2STATinMED Research, Plano, TX, USA, 3Amgen, Inc., Thousand Oaks, CA, USA, 4STATinMED Research, Columbia University, New York, NY, USA

PCV59
C16
THE INCREMENTAL COST OF REOPERATIONS FOR BLEEDING EVENTS IN CARDIAC AND VASCULAR RECONSTRUCTIVE SURGERY
Gunnarsson C1, Lim S2, David G3, Riebman JB2, Martin L4, Kocharian R2
1CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA, 2Ethicon, Inc., Somerville, NJ, USA, 3The Wharton School, University of Pennsylvania, Philadelphia, PA, USA, 4Johnson & Johnson Medical Products, Markham, ON, Canada

PCV60
D1
COST EFFECTIVENESS OF STATINS IN PRIMARY PREVENTION OF CORONARY HEART DISEASE: A SYSTEMATIC REVIEW AND QUALITY ASSESSMENT OF ECONOMIC EVIDENCE TO ELUCIDATE RECENT TRENDS IN USA
Bardia A1, Garg G2
1Invaluesys Research, Hyderabad, India, 2Invaluesys Research, Burgdorf, Germany

PCV61
WITHDRAWN

PCV62
D2
ANNUAL MEDICATION COST ATTRIBUTED TO EACH KIND OF TREATMENT OF PATIENTS SUBJECTED TO CRMDS IMPLANTATION
Fanourgiakis JA1, Simantirakis E2, Kanoupakis E2, Chrysostomakis S2, Maniadakis N3, Kourlamba G3, Vardas P2
1Department of Cardiology, Heraklion University Hospital, Crete, Greece. Department of Accounting and Finance, School of Economics and Management, T.E.I. Heraklion, Crete, Greece. Department of Business Administration, T.E.I. Agios Nikolaos, Crete, Greece, Heraklion, Greece, 2Department of Cardiology, Heraklion University Hospital, Heraklion, Greece, 3Department of Health Services Management, National School of Public Health, Athens, Greece, Athens, Greece

PCV63
D3
COST-EFFECTIVENESS OF STRATEGIES FOR MANAGEMENT OF DEEP VEIN THROMBOSIS
Kostyuk A1, Akanov A2, Almadiyeva A2
1Kazakh Medical University for Continuing Education, Astana, Kazakhstan, 2Astana Medical University, Astana, Kazakhstan

PCV64
D4
ECONOMIC EVALUATION OF DABIGATRAN ETEXILATE FOR THE TREATMENT OF DEEP VENOUS THROMOEMBOLISM AND PULMONARY EMBOLISM
Huicochea-Bartelt JL1, Ortiz-Blas LA2, Herran S1, Gay-Molina J2, Robledo JL1
1Boehringer Ingelheim, Distrito Federal, Mexico, 2Tecnología e Informática para la Salud, Distrito Federal, Mexico

PCV65
D5
COST-EFECTIVENESS OF DABIGATRAN IN NON VALVULAR ATRIAL FIBRILLATION IN COLOMBIA
Triana JJ1, Castañeda-Cardona C1, Parada L2, Rosselli D1
1Pontificia Universidad Javeriana, Bogota, Colombia, 2Boehringer Ingelheim, Bogota, Colombia

PCV66
D6
ECONOMIC EVALUATION OF DABIGATRAN ETEXILATE VERSUS WARFARIN, RIVAROXABAN AND APIXABAN IN STROKE PREVENTION IN ATRIAL FIBRILATION
Huicochea-Bartelt JL1, Gay-Molina J2, Ortiz-Blas LA2, Herran S1
1Boehringer Ingelheim, Distrito Federal, Mexico, 2Tecnología e Informática para la Salud, Distrito Federal, Mexico

PCV67
D7
COST-EFFECTIVENESS ANALYSIS OF SIMVASTATIN ATORVASTATIN AND ATORVASTATIN-EZETIMIBE COMBINATION AMONG PATIENTS WITH DIABETES MELLITUS OR CARDIOVASCULAR DISEASE IN GENERAL PRACTICE
Rattanakunooprakarn H1, Tewthanom K1, Sakthong P2
1Silapakorn University, Meaung, Thailand, 2Chulalongkorn University, Phatumwan, Thailand

PCV68
D8
CLOPIDOGREL VERSUS ASPIRIN IN PATIENTS WITH ATHEROTHROMBOSIS: A CAPRIE-BASED ECONOMIC ANALYSIS IN A HEALTH RESOURCE LIMITED SETTING
Li T1, Liu MB2, Ben H3, Xu ZX4, Zhong H5, Wu B5
1Department of Pharmacy, Yuxi People’s Hospital, Yuxi, China, 2Department of Pharmacy, Fujian Union Hospital, Fujian, China, 3Department of Cardiology, Ren Ji Hospital, Shanghai, China, 4Department of Cardiology, Gongli Hospital, Shanghai, China, 5Department of General Surgery, Ren Ji Hospital, Shanghai, China

PCV69
D9
COST-EFFECTIVENESS OF RIOCIGUAT FOR TREATMENT OF PATIENTS WITH INOPERABLE OR POST-OPERATIVE RECURRENT/PERSISTENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) IN TURKEY
Erdal E1, Ozdemir O2, Yildizeli B3, Kaymaz C4, Okumus G5, Mogulkoc N6, Nalbantgil S6, Deger C7, Sumer F7, Parali E7, Tunalioglu A1, Sar C1, Asan S7, Ozel O1
1Bayer Turk Kimya San. Ltd. Sti, Istanbul, Turkey, 2Yorum Consultancy, Istanbul, Turkey, 3Marmara University Faculty of Medicine, Istanbul, Turkey, 4Kosuyolu Training and Research Hospital, Istanbul, Turkey, 5Istanbul University Faculty of Medicine, Istanbul, Turkey, 6Ege University Faculty of Medicine, Izmir, Turkey, 7Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey

PCV70
D10
COMPARATIVE COST-EFFECTIVENESS ANALYSIS OF CATHETER DIRECTED THROMBOLISYS WITH UROKINASE AND ALTEPLASE FOR TREATMENT OF ACUTE PERIPHERAL ARTERY DISEASE
Kostyuk A1, Akanov A2, Almadiyeva A2
1Kazakh Medical University for Continuing Education, Astana, Kazakhstan, 2Astana Medical University, Astana, Kazakhstan

PCV71
WITHDRAWN

PCV72
D11
COST EFFECTIVENESS ANALYSIS OF APIXABAN COMPARED TO ORAL ANTICOAGULANTS IN THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN GUATEMALA IN 2014
Garita-Aguilar M1, Peralta-Acon M1, Jiménez-Crespo L2
1Pfizer Central America and Caribbean, San José, Costa Rica, 2Instituto Guatemalteco del Seguro Social, Ciudad de Guatemala, Guatemala

PCV73
D12
COST EFFECTIVENESS OF APIXABAN FOR STROKE PREVENTION IN NON VALVULAR ATRIAL FIBRILLATION IN THE ECUATORIAN PUBLIC HEALTHCARE SECTOR
Rosado-Buzzo A1, Albuja M2, Garcia-Molliendo L3, Luna-Casas G3
1Linkd and Links, Mexico City, Mexico, 2Pfizer Ecuador, Quito, Mexico, 3Links and Links, Mexico City, Mexico

PCV74
D13
COST-EFFECTIVENESS ANALYSIS AMONG PATIENTS WITH DIABETES MELLITUS OR CARDIOVASCULAR DISEASE RECEIVING SECOND-LINE TREATMENT WITH INTENSIVE DOSES OF SIMVASTATIN ATORVASTATIN AND ATORVASTATIN-EZETIMIBE COMBINATION IN GENERAL PRACTICE
Tewthanom K1, Rattanakunooprakarn H1, Sakthong P2
1Silapakorn University, Meaung, Thailand, 2Chulalongkorn University, Phatumwan, Thailand

PCV75
WITHDRAWN

PCV76
D14
SYSTEMATIC REVIEW OF RECENT PHARMACOECONOMIC EVALUATIONS RELATED TO GENOTYPE-GUIDED THERAPY IN PATIENTS AT HIGH RISK FOR THROMBOTIC EVENT
Smith SA
University of Texas at Austin, Austin, TX, USA

PCV77
D15
COST EFFECTIVENESS OF AN ANTICOAGULANT CLINIC AFTER INTRODUCTION OF NOACS FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES
Alhazami M1, Holdford DA2
1virginia commonwealth university, glen allen, VA, USA, 2virginia commonwealth university, richmond, VA, USA

PCV78
D16
THE COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE COMPARED WITH EDOXABAN IN THE TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM IN THE UK
Jugrin AV1, Ustyugova AV2, Lamotte M3, Sunderland TJ4
1IMS Health HEOR, Vilvoorde, Belgium, 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, 3IMS Health, Vilvoorde, Belgium, 4Boehringer Ingelheim UK, Berkshire, UK

PCV79
E1
DOES AZILSARTAN MEDOXIMIL – CHLORTHALIDONE LOWER RISK OF CORONARY HEART DISEASE THAN OLMESARTAN MEDOXIMIL – HYDROCHLORTHIAZIDE IN PATIENTS WITH ESSENTIAL HYPERTENSION: A COST-EFFECTIVE ANALYSIS
Bhansali A1, Sansgiry SS2
1University of Houston College of Pharmacy, Houston, TX, USA, 2University of Houston, Houston, TX, USA

PCV80
E2
COST-MINIMIZATION ANALYSIS OF TINZAPARIN SODIUM COMPARED TO OTHER LOW-MOLECULAR-WEIGHT HEPARINS FOR PATIENTS WITH DEEP VENOUS THROMBOSIS
Diaz JP1, Soto Molina H2, Marquez M3, Escobar Juárez Y2
1Universidad Nacional Autonoma de Mexico, México D.F., Mexico, 2HS Estudios Farmacoeconómicos, Mexico City, Mexico, 3Universidad Autonoma Metropolitana, México D.F., Mexico

PCV81
E3
COST-UTILITY ANALYSIS OF APIXABAN IN PATIENTS WITH ATRIAL FIBRILLATION (AF) AT THE PERUVIAN SOCIAL SECURITY (ESSALUD)
Sanabria C1, Cabrejos J1, Garrido Lecca S2, Olortegui A3, Guevara C3
1Universidad Nacional Mayor de San Marcos, Lima, Peru, 2Bristol-Myers Squibb, Lima, Peru, 3Instituto Nacional Cardiovascular (INCOR), Lima, Peru

PCV82
E4
COST EFFECTIVENESS OF DRUGS FOR PULMONARY ARTERIAL HYPERTENSION: A CANADIAN STUDY
Coyle K1, Coyle D2, Jabr M3, Blouin J3, Lee K3
1Brunel University, Uxbridge, UK, 2University of Ottawa, Ottawa, ON, Canada, 3CADTH, Ottawa, ON, Canada

PCV83
E5
REAL-WORLD OUTCOMES OF ACUTE ISCHEMIC STROKE PATIENTS IN THE MEDICARE POPULATION
Watson C1, Burudpakdee C2, Noone J2, Seetasith A3, Nyandege A3
1Biogen Idec, Cambridge, MA, USA, 2University of North Carolina at Charlotte, Charlotte, NC, USA, 3Market Access Solutions LLC, Raritan, NJ, USA

PCV84
E6
THE TOTAL DIRECT HEALTHCARE COST OF AORTIC AND MITRAL VALVULAR DISEASE: EVIDENCE FROM US NATIONAL SURVEY DATA
Rizzo JA1, Chen J2, Mallow PJ3, Moore M4
1Stony Brook University, Stony Brook, NY, USA, 2University of Maryland, College Park, NY, USA, 3CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA, 4Edwards Lifesciences, Inc., Irvine, CA, USA

CARDIOVASCULAR DISORDERS - Patient-Reported Outcomes & Patient Preference Studies
PCV85
E7
PERSISTENCE AND COMPLIANCE WITH LIPID- LOWERING DRUGS IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Truong VT, Moisan J, Kröger E, Langlois S, Gregoire J
Laval University, Quebec, QC, Canada

PCV86
E8
INERTIA OR ACTUAL SWITCHING ON MEDICATON ADHERENCE AND ECONOMIC WELL-BEING OF MEDICARE BENEFICIARIES ENROLLED IN PART D PLANS
Basu R
Baylor Scott & White Health, Temple, TX, USA

PCV87
E9
COMPLIANCE AND CONTROL OF HYPERTENSION WITH CO-MORBIDITIES IN PRIMARY CARE IN UKRAINE
Korzh O
Kharkov Medical Academy of Postgraduate Education, Kharkov, Ukraine

PCV88
E10
COMPARING THE EQ-5D-3L AND SF-6D UTILITY SCORES OF ACUTE CORONARY SYNDROME PATIENTS FROM AN ASIAN POPULATION
Azmi S1, Anchah L2, Goh A1, Fong A3
1Azmi Burhani Consulting, Petaling Jaya, Malaysia, 2Sarawak General Hospital Heart Centre, Kuching, Malaysia, 3Sarawak General Hospital, Kuching, Malaysia

PCV89
E11
HEALTH UTILITIES OF HYPERTENSIVE PATIENTS IN VIETNAM
Nguyen TP, C.C.M. S, Postma MJ
Groningen University, Groningen, The Netherlands

PCV90
E12
DETERMINANTS OF UTILITY BASED ON THE EQ-5D IN CHRONIC HEART FAILURE PATIENTS AND THEIR CHANGE OVER TIME: RESULTS FROM THE SWEDISH HEART FAILURE REGISTRY
Berg J1, Lindgren P2, Mejhert M3, Edner M4, Dahlström U5, Kahan T6
1Mapi, Stockholm, Sweden, 2IVBAR, Stockholm, Sweden, 3Ersta Hospital, Stockholm, Sweden, 4Karolinska Institutet, Stockholm, Sweden, 5Linköping University, Linköping, Sweden, 6Danderyd Hospital, Stockholm, Sweden

PCV91
E13
VALIDATION OF A SYNDROME-SPECIFIC INSTRUMENT TO ASSESS ANGINA TREATED BY TRADITIONAL CHINESE MEDICINE (TCM-SAQ): THE ABILITY TO DETECT CHANGE
Zhang HY, Yu L, Lv MJ, Chen ZH, Yang GL
Liaoning University of Traditional Chinese Medicine, Shenyang, China

PCV92
E14
TRAJECTORIES OF ANGINA HEALTH-RELATED QUALITY OF LIFE AFTER ACUTE CORONARY SYNDROME IN TRACE-CORE
Nobel L1, Tjia J2, Saczynski JS1, Waring ME1, Anatchkova MD1, Ware J1, Ash AS1, Kiefe CI1, Allison JJ1
1University of Massachusetts Medical School, WORCESTER, MA, USA, 2University of Massachusetts Medical School, Worcester, MA, USA

CARDIOVASCULAR DISORDERS - Health Care Use & Policy Studies
PCV93
E15
IMPLEMENTATION OF THE AMERICAN DIABETES ASSOCIATION'S STANDARDS OF MEDICAL CARE: THE CASE OF STATIN UTILIZATION IN THE ELDERLY WITH DIABETES
Li M, Lu K, Maxwell WD, Schulz RM
University of South Carolina, Columbia, SC, USA

PCV94
E16
PATIENTS IN THE WAITING LIST OF BARIATRIC SURGERY IN THE BRAZILIAN PUBLIC SECTOR TREATMENT PATTERNS AND HEALTH OUTCOMES: A NON-INTERVENTIONAL SINGLE-SITE RETROSPECTIVE STUDY
Junqueira Junior SM1, Luque A1, Cabra HA2, Andrade PC1, Oliveira FM3, Brasil N1, Rasera I4
1Johnson&Johnson Medical Brazil, Sao Paulo, Brazil, 2Johnson & Johnson Medical, Mexico, D.F., Mexico, 3Johnson & Johnson Medical Brazil, São Paulo, Brazil, 4Clinica Bariátrica, São Paulo, Brazil

PCV95
F1
A CONSERVATIVE APPROACH TO ASSESS WARFARIN TIME-IN-THERAPEUTIC RANGES AMONG NONVALVULAR ATRIAL FIBRILLATION PATIENTS IN AN INTEGRATED HEALTHCARE DELIVERY SYSTEM SETTING IN THE U.S
Deitelzweig S1, Evans M2, Hillson E3, Trocio J4, Bruno A3, Tan W4, Lingohr-Smith M5, Lin J5
1Ochsner Medical Center, New Orleans, LA, USA, 2Geisinger Health System, Danville, PA, USA, 3Bristol-Myers Squibb, Plainsboro, NJ, USA, 4Pfizer, New York, NY, USA, 5Novosys Health, Green Brook, NJ, USA

PCV96
F2
ANALYSIS OF KENTUCKY MEDICAID MANAGED CARE VERSUS FEE-FOR-SERVICE SYSTEMS: MEDICATION ADHERENCE IN PATIENTS WITH ESSENTIAL HYPERTENSION
Herren C, Brouwer E, Talbert J
University of Kentucky College of Pharmacy, Lexington, KY, USA

PCV97
F3
THE 5 PRINCIPAL CAUSES OF DEATH IN MEXICO IN THE LAST 5 YEARS, IS THE PUBLIC HEALTH SYSTEM COVERING THESE NEEDS?
Lemus F1, Rivas R2
1National Institute of Public Health, Estado de México, Mexico, 2National Institute of Public Health, Naucalpan de Juarez, Mexico

PCV98
F4
SOCIOECONOMIC FACTORS AND PRESCRIBED MEDICINES EXPENDITURES ASSOCIATED WITH ANTIHYPERLIPIDEMIC THERAPY; A COMPARISON BETWEEN HYPERLIPIDEMIA PATIENTS WITH AND WITHOUT TREATMENT
Althemery AU, Alfaifi A, Lai L
Nova Southeastern University, Davie, FL, USA

PCV99
F5
THE USE OF STATINS AMONG PRIOR-USERS AFTER HEMODIALYSIS
Shih Y1, Liu Y1, Huang W1, Wen Y2, Tsai Y1
1National Yang Ming University, Taipei, Taiwan, 2Chang Gung University, Taoyuan, Taiwan

PCV100
F6
AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM USAGE IN CROATIA DURING THE FOURTEEN-YEAR PERIOD: IMPACT OF GENERICS
Vitezic D1, Kucan M2, Mrsic Pelcic J3, Vitezic M4
1University of Rijeka, School of Medicine and University Hospital Centre Rijeka, Rijeka, Croatia, 2JGL dd, Rijeka, Rijeka, Croatia, 3University of Rijeka Medical School, Rijeka, Croatia, 4University Orthopaedic Clinic Lovran and University of Rijeka Medical School, Lovran, Croatia

PCV101
F7
RESULTS OF AN INTERVENTION IN PRESCRIPTION OF CONVENTIONAL RELEASE VERAPAMIL IN PATIENTS WITH HYPERTENSION IN COLOMBIA
Machado J, Machado-Duque M, Giraldo C
Universidad Tecnológica de Pereira, Pereira, Colombia

PCV102
F8
DRUG USE AMONG SENIORS ON PUBLIC DRUG PROGRAMS IN CANADA, 2012
Proulx J
CIHI, Ottawa, ON, Canada

PCV103
F9
GENERIC DRUG DISCOUNT PROGRAMS AND THEIR POTENTIAL IMPACT ON THE COMPLETENESS OF PHARMACY CLAIMS DATA
Thompson JA, Kelton CM, Heaton PC
University of Cincinnati, Cincinnati, OH, USA

PCV104
F10
TIMELY USE OF ACE INHIBITORS AND ARBS AFTER NEWLY DIAGNOSED DIABETES AMONG OLDER ADULTS WITH HYPERTENSION IN THE U.S
Bogart M, Fang G, Annis I
UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA

PCV105
F11
GAPS IN STATINS USE AMONG OLDER ADULTS WITH NEW ONSET DIABETES IN THE US
Chung TA, Bogart M, Annis I, Fang G
UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA

PCV106
F12
INFLUENCE OF COST SHARING DIFFERENTIALS ON THERAPEUTIC SUBSTITUTION AND MEDICATION ADHERENCE: THE STORY OF STATINS IN 2006
Li P, Schwartz SJ, Doshi JA
University of Pennsylvania, Philadelphia, PA, USA

PCV107
F13
DIRECT MEDICAL COST COMPARISON BETWEEN PATIENTS RECEIVING CANGRELOR AND CLOPIDOGREL DURING PERCUTANEOUS CORONARY INTERVENTION: CHAMPION PHOENIX ECONOMIC SUB-STUDY RESULTS
Nicholson G1, Cyr P2, Fan W3, Plent S3
1ICON, plc., El Segundo, CA, USA, 2ICON Plc, Dublin, Ireland, 3The Medicines Company, Parsippany, NJ, USA

PCV108
F14
HOSPITALIZATION COSTS FOR PATIENTS WITH HEART FAILURE USING CLAIMS DATABASE – A COMPARISON BETWEEN COMMERCIAL AND MEDICARE ADVANTAGE POPULATION
Kielhorn A1, Maya J1, Song R2, Henk HJ2, Patel H1
1Amgen, Thousand Oaks, CA, USA, 2Optum, Eden Prairie, MN, USA

PCV109
F15
CURRENT RESOURCE UTILIZATION PATTERNS IN MEDICARE BENEFICIARIES DIAGNOSED WITH HEART FAILURE
Patel H1, Sharma P2, Maya J1, Kilgore M2, Kielhorn A1
1Amgen, Thousand Oaks, CA, USA, 2Univeristy of Alabama at Birmingham, Birmingham, AL, USA

PCV110
F16
BASELINE DEMOGRAPHICS AND CLINICAL CHARACTERISTICS ASSOCIATED WITH HEALTHCARE COSTS AMONG PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
Power TP1, Ke X2, Zhao Z3, Bonine N2, Cziraky MJ2, Grabner M2, Barron J4, Quimbo R2, Wertz D2, Flickinger DM3, Vangerow B3, Toth PP5
1AIM Specialty Health, Chicago, IL, USA, 2HealthCore Inc., Wilmington, DE, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4HealthCore, Inc, Wilmington, DE, USA, 5CGH Medical Center, Sterling, IL, USA

PCV111
WITHDRAWN

PCV112
G1
ANNUAL HOSPITALIZATION FREQUENCY FOR PATIENTS WITH HEART FAILURE - A COMPARISON BETWEEN COMMERCIAL AND MEDICARE ADVANTAGE POPULATION
Patel H1, Maya J1, Song R2, Henk HJ2, Kielhorn A1
1Amgen, Thousand Oaks, CA, USA, 2Optum, Eden Prairie, MN, USA

PCV113
G2
ASSESSING THE HEALTH CARE RESOURCE UTILIZATION AND ECONOMIC BURDEN AMONG U.S. CARDIOVASCULAR DISEASE PATIENTS IN THE VETERANS HEALTH ADMINISTRATION POPULATION
Mao X1, Shrestha S2, Baser O3, Wang L2
1University of Texas at Dallas and STATinMED Research, Plano, TX, USA, 2STATinMED Research, Plano, TX, USA, 3STATinMED Research, Columbia University, New York, NY, USA

PCV114
G3
STUDY ON THE INPATIENT HOSPITAL COSTS OF HEMORRHAGIC STROKE INPATIENTS IN CHINA
Ma Y, Li Z, Wang L
China Health Insurance Research Association, Beijing, China

PCV115
G4
EVIDENCE REQUIREMENTS FOR FUTURE ANTIARRHYTHMIC TREATMENTS FOR ATRIAL FIBRILLATION (AF)
Black J, Proach J
Market Access Solutions LLC, Raritan, NJ, USA

PCV116
G5
ASSESSMENT OF PAYER WILLINGESS TO PAY FOR NOVEL HEART FAILURE THERAPIES: INCREMENTAL IMPROVEMENT IN SYMPTOM RELIEF VERSUS DISEASE MODIFYING
Proach J, Cromer K, Black J
Market Access Solutions LLC, Raritan, NJ, USA

PCV117
G6
THE BURDEN OF UNCERTAINTY IN EMERGENCY ROOM: THE CASE OF CHEST PAIN
Abbass IM1, Nassar A2
1The University of Texas Health Sciences Center at Houston, Houston, TX, USA, 2Texas Woman's University, Houston, TX, USA

PCV118
G7
IMPACT OF MEDICAID DISCONTINUITY ON HEALTH CARE RESOURCE UTILIZATION AMONG NON-ELDERLY ADULTS WITH CARDIOVASCULAR DISEASE
Munshi KD1, Bailey JE1, Relyea G2
1University of Tennessee Health Science Center, Memphis, TN, USA, 2University of Memphis, Memphis, TN, USA

PCV119
G8
EVALUATING THE OUTCOMES OF A DIABETES TREATMENT MANAGEMENT PROGRAM TARGETING APPROPRIATE ANTI-HYPERTENSIVE TREATMENT FOR ADULTS WITH DIABETES FOR DUAL AND NON-DUAL ELIGIBLE MEDICARE ADVANTAGE BENEFICIARIES
Leung K1, Sendzik J1, Lee GC2
1Anthem, Norfolk, VA, USA, 2The University of Texas at Austin and UT Health Science Center at San Antonio, San Antonio, TX, USA

PCV120
G9
THE IMPACT OF DIFFERENT TYPES OF HEALTH INSURANCE ON THE HOSPITALIZATION SERVICES UTILIZATION OF PATIENTS WITH HEMORRHAGIC STROKE IN CHINA
Ma Y, Xiong X, Li J, Zhang J
China Health Insurance Research Association, Beijing, China

PCV121
G10
THE EXPANSION OF STROKE CENTERS AND THE REDUCTION OF IN-HOSPITAL MORTALITY OF ISCHECHEMIC STROKE PATIENTS IN ALBERTA
Ohinmaa A1, Zheng Y1, Jeerakathil T1, Thanh NX2, Klarenbach S1, Hakkinen U3, Friesen D4, Kaul P1, Ruseski J5, Ariste R6, Jacobs P2
1University of Alberta, Edmonton, AB, Canada, 2Institute of Health Economics, Edmonton, AB, Canada, 3National Institute for Health and Welfare, Helsinki, Finland, 4Alberta Medical Association, Edmonton, AB, Canada, 5West Virginia University, Morgantown, WV, USA, 6Canadian Institute for Health Information, Ottawa, ON, Canada

PCV122
G11
THE IMPACT OF STROKE CENTERS ON THE LENGTH OF STAY AMONG ISCHECHEMIC STROKE PATIENTS IN ALBERTA
Ohinmaa A1, Zheng Y1, Jeerakathil T1, Nguyen T2, Klarenbach S1, Hakkinen U3, Kaul P1, Friesen D4, Ruseski J5, Ariste R6, Jacobs P2
1University of Alberta, Edmonton, AB, Canada, 2Institute of Health Economics, Edmonton, AB, Canada, 3National Institute for Health and Welfare, Helsinki, Finland, 4Alberta Medical Association, Edmonton, AB, Canada, 5West Virginia University, Morgantown, WV, USA, 6Canadian Institute for Health Information, Ottawa, ON, Canada

PCV123
G12
PHARMACOECONOMICS RESEARCH ON DIABETES AND HYPERTENSION IN INDIA: A STUDY BASED ON PUBMED DATABASE
Dharmagadda S1, Vooradi S2, Mateti UV1
1Dept. of Pharmacy Management, MCOPS, Manipal University, Manipal, India, 2Dept. of Pharmacy Practice, MCOPS, Manipal University, Manipal, India

PCV124
G13
RISK OF DIABETES WITH OR WITHOUT THE PRESENCE OF OTHER OBESITY-RELATED COMORBIDITIES (HYPERTENSION, STROKE AND CORONARY HEART DISEASE): NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, 2007-2010
Leung MY, Carlsson NP, Colditz GA, Chang S
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, St. Louis, MO, USA

PCV125
G14
FUNCTIONAL STATUS AND DIFFICULTY IN ACTIVITIES OF DAILY LIVING AMONG AGING POPULATION OF INDIA
Sakharkar P1, Sakharkar V2
1Roosevelt University College of Pharmacy, Schaumburg, IL, USA, 2UWI-School of Clinical Medicine and Research, Nassau, Bahamas

PCV126
G15
PREVALENCE AND OUTCOMES OF GLOBAL VASCULAR HOSPITAL ADMISSIONS IN ARGENTINA
Insua J
Hospital Universitario Austral, Pacheco, Argentina

PCV127
G16
DEPRESSION TREATMENT AMONG WOMEN WITH CARDIO-METABOLIC CONDITIONS: FINDINGS FROM MEDICAL EXPENDITURE PANEL SURVEY 2012
Raval A, Sambamoorthi U
West Virginia University, Morgantown, WV, USA

PCV128
G17
PATTERNS OF TREATMENT MODIFICATIONS IN NEWLY TREATED HYPERTENSIVE PATIENTS: DOES CHOICE OF MODIFICATION STRATEGY AFFECT LIKELIHOOD OF TREATMENT DISCONTINUATION?
Sonawane KB1, Qian J1, Garza KB1, Wright BM1, Zeng P1, Ganduglia Cazaban CM2, Hansen RA1
1Auburn University, Auburn, AL, USA, 2University of Texas School of Public Health, Houston, TX, USA

PCV129
G18
REAL-WORLD STATIN UTILIZATION AMONG PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS: US ANALYSES
Lin I1, Sung JC2, Sanchez R3, Mallya UG2, Friedman M1, Panaccio M2, Koren A2, Neumann PJ4, Menzin J1
1Boston Health Economics, Inc., Waltham, MA, USA, 2Sanofi US, Inc., Bridgewater, NJ, USA, 3Regeneron Pharmaceuticals, Tarrytown, NY, USA, 4Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA

PCV130
G19
TREATMENT PATTERN AND OUTCOMES OF INTRAVENOUS ANTIHYPERTENSIVE AGENTS IN US HOSPITAL ICH PATIENTS
Wang Y, Plent S, Crothers TA
The Medicines Company, Parsippany, NJ, USA

PCV131
G20
VENOUS THROMBOEMBOLISM TREATMENT PATTERNS IN THE EUROPEAN UNION (EU) REGION: 2013 RETROSPECTIVE CHART EXTRACTION
Gupta S1, Goren A2, Yaniv R3, Unniachan S4, Phatak H5, Masseria C6, Hamilton M7, Liu X3
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA, 3Pfizer Inc, New York, NY, USA, 4Bristol- Myers Squibb, Princeton, NJ, USA, 5Bristol-Myers Squibb Company, Princeton, NJ, USA, 6Pfizer Inc., New York, NY, USA, 7BMS, Princeton, NJ, USA

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.